Nemvaleukin alfa

Mural Oncology anticipates key data readouts for nemvaleukin alfa trials in 2025 for platinum-resistant ovarian cancer and mucosal melanoma, with preliminary data for cutaneous melanoma also expected. The company nominated two new candidates, MURA-8518 and MURA-7012, aiming for IND submission in Q4 2025. Operational efficiencies extended cash runway into Q1 2026.

Mural Oncology anticipates key data readouts for nemvaleukin alfa in 2025 for platinum-resistant ovarian cancer and mucosal melanoma, with interim analysis of ARTISTRY-7 expected late Q1/early Q2 2025. The company also plans IND submission for MURA-8518 in Q4 2025, extending its cash runway into Q1 2026.

Mural Oncology plc (MURA) closed at $3.6500, up 5.19%, focusing on cancer immunotherapies, including nemvaleukin alfa for mucosal melanoma and ovarian cancer. With a market cap of $62.27M, it's developing IL-18 and IL-12 programs. YTD return: 15.87% vs. S&P 500's 0.19%.

Mural Oncology anticipates 2025 catalysts, including data readouts for nemvaleukin trials in ovarian cancer and mucosal melanoma, and plans for IND submission for MURA-8518. The company extended its cash runway to Q1 2026, highlighting progress in its cytokine-based immunotherapies pipeline aimed at addressing unmet cancer treatment needs.

The Ovarian Cancer market is expected to grow significantly by 2034, driven by advancements in treatments from companies like AbbVie and Verastem Oncology. Key insights include decreasing diagnosed cases, emerging therapies, and FDA approvals for new treatments. The report covers epidemiology, market trends, and therapeutic developments in the US, EU4, UK, and Japan.

Mural Oncology focuses on engineered cytokine therapies for cancer, with lead candidate Nemvaleukin alfa. Key trials ARTISTRY-7 and ARTISTRY-6 are underway, with data readouts expected in 2025. The company plans a Biologics License Application submission based on ARTISTRY-7 results. Mural ended September 2024 with $175.5 million in cash.

Trump's deregulatory economic policy and favorable seasonal period for the economy have analysts optimistic about market growth. Raymond James highlights Mural Oncology (MURA) and Disc Medicine (IRON) as stocks with significant upside potential, with MURA potentially gaining nearly 440% and IRON around 70%.